CEO COMMENTS

Kristina Torfgård comments Q3 report 2025

“In recent months, we have taken several important steps in the development of our leading drug projects. Preparations for the Phase Ib study of IRL757 are progressing according to plan, and we have strengthened the commercial position of mesdopetam through new patent protection. During the quarter, a rights issue was carried out, providing the necessary capital and resources for the continued development of our drug candidates IRL1117 and pirepemat. We are also pleased to welcome Gustaf Albèrt as our new CFO, and the management team now continues to execute our strategy with full focus and determination.

Key Milestones During the Quarter and after:

• IRLAB’s partner MSRD issued a payment of USD 4 million for the fully funded study of IRL757 in Parkinson’s disease, which is progressing according to plan.
• An application to initiate a Phase Ib study of IRL757 in individuals with Parkinson’s disease and apathy was submitted to the EMA, and patient recruitment is expected to begin by the end of 2025.
• The recently granted patent for mesdopetam in China further strengthens the already robust patent and exclusivity protection, with potential market exclusivity well into the 2040s in all major markets.
• The rights issue has provided resources for the next development phase of two of IRLAB’s unique drug projects, IRL1117 and pirepemat – with the manufacturing of the drug substance now initiated.

Together, these advances demonstrate that IRLAB is well on its way to realizing its vision and creating value for patients, partners, and shareholders.”

Q4’24

Year-end report >

Presentation >

Webcast >

Q1’25

Interim report >

Presentation >

Webcast >

Q2’25

Interim report >

Presentation >

Webcast >

Q3’25

Interim report >

Presentation >

Webcast >

FINANCIAL CALENDAR

NEXT

February 11 2026

Year-end report 2025